Latest news
![](/images/news/VROOM-trial-full-results-hero-image.png)
Over 1 million people with weakened immune systems can improve protection against COVID-19 by pausing their medication for 2 weeks after their booster jab.
- Published:
13 December 2023
![](/images/news/remap-cap-trial-vitamin-c-hero-image.png)
The findings are part of the ongoing REMAP-CAP trial which is funded and supported by NIHR.
- Published:
25 October 2023
![](/images/news/Covid_report.jpg)
NIHR Applied Research Collaborations (ARCs) have launched a report looking at their contribution to the fight against COVID-19.
![](/images/news/panoramic.jpg)
It will find out if antibody testing can identify which immunosuppressed people remain at greatest risk of severe COVID-19 infection after vaccinations.
![](/images/news/remap-cap-flu.jpg)
The REMAP-CAP study is funded and delivered by NIHR and aims to use pandemic lessons to find effective treatments for people hospitalised with severe flu.
- Published:
29 November 2022
![](/images/news/blood-graphic.jpg)
The HEAL-COVID study has found that a drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19.
- Published:
28 November 2022
![HPRU covid infection 5 days](/images/news/HPRU-covid-infection-5-days.png)
A new NIHR funded study of 57 people with mild COVID-19 estimates how long people are infectious for and when they can safely leave isolation.
- Published:
19 August 2022
![COVID-19 vaccine being delivered](/images/news/Moderna%20COVID-19%20Omicron%20Booster%20-%20NIHR%20News%20item.png)
NIHR-supported Moderna Omicron bivalent COVID-19 vaccine booster receives UK approval from MHRA
- Published:
15 August 2022
![](/images/news/COVID%20distress%20hero%20image.png)
People in England continued to feel distressed even after all legal COVID-19 restrictions ended in February 2022, suggests new research funded by the NIHR.
- Published:
05 August 2022
![hair loss long covid story](/images/news/hair-loss-long-covid-story.png)
A study funded by NIHR and UK Research and Innovation has found that people with long COVID experience a wider set of symptoms than previously thought, including hair loss and sexual dysfunction.
![pregnant women recieving COVID-19 vaccine](/images/news/Preg-Cov%20COVID-19%20Vaccine%20Study%20Banner.png)
Preg-CoV, a COVID-19 vaccine study, is calling on pregnant women to join hundreds of volunteers and help researchers find the most effective use of boosters.
![](/images/news/older-woman-at-home-long-covid.jpg)
Women, people aged 50-60, and people with poor pre-pandemic mental or physical health are more at risk of long COVID, according to research funded by the NIHR and UK Research and Innovation.
![](/images/news/vrrom-results-image.jpg)
Interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination can double their antibody response to the jab, new research finds.
![](/images/news/vaccine-injection-web.jpg)
A standard two-dose Pfizer-BioNTech or Oxford-AstraZeneca vaccine schedule showed a greater antibody increase when given at a 12-week interval, compared to a four-week interval.
![](/images/news/long-covid-symptoms-decrease-with-vacination-news-story.jpg)
An NIHR-supported study of more than 28,000 people has shown that vaccination against COVID-19 is associated with a moderate reduction in the risk of experiencing long COVID.
![](/images/news/Teenager-covid-vaccine.jpg)
Com-COV 3 to test multiple options for third booster dose COVID-19 vaccines for young people aged 12 to 15 years old
![COV-BOOST Study results of 4th COVID-19 vaccine dose](/images/news/Cov-Boost%20News%20Item%20.png)
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from the NIHR-supported COV-BOOST study.
![](/images/news/mature-woman-with-long-covid.jpg)
Researchers have worked with patients to develop a comprehensive tool to assess the symptoms of long COVID and their impact on everyday life.
![](/images/news/Cov-Boost%20Study%20-%20NIHR%20Site%20Header%20Image.png)
The latest results from the UK’s COV-BOOST study, led by University Hospital Southampton, have shown prolonged immune responses following third doses of several COVID-19 vaccines.
![](/images/news/valneva-phase-3.png)
Following rigorous clinical trials supported by the NIHR and thorough data analysis, the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the Valneva COVID-19 vaccine for UK use.
![](/images/news/panoramic.jpg)
The NIHR-supported PANORAMIC trial is investigating a new COVID-19 antiviral treatment, Paxlovid, among vulnerable groups in the community.
![](/images/news/genomic-sequencing.jpg)
The world’s largest study of the genetics of critical COVID-19, has revealed details about some of the biological mechanisms behind the severe form of the disease
![](/images/covid-lungs.jpg)
The NIHR-supported RECOVERY trial has found that baricitinib, an anti-inflammatory rheumatoid arthritis drug, reduces deaths in patients hospitalised for COVID-19 by around one-fifth.
![COVID-19 vaccine being delivered](/images/news/Moderna%20COVID-19%20Omicron%20Booster%20-%20NIHR%20News%20item.png)
One of the world’s first Omicron-specific COVID-19 variant vaccines is to be trialled at multiple sites across the UK, as the biotechnology company Moderna, Inc works alongside the NIHR.
- Published:
16 February 2022
![](/images/news/long-covid-adult-child-at-home.jpg)
Researchers have developed new definitions for what long COVID is and the key effects in children and adults, which will help harmonise research and improve understanding of the condition.
- Published:
08 February 2022